Versanis Bio

Oakland, United States Founded: 2020 • Age: 6 yrs Acquired By Lilly
Developer of therapeutics for the treatment of obesity
Request Access

About Versanis Bio

Versanis Bio is a company based in Oakland (United States) founded in 2020 was acquired by Lilly in July 2023.. Versanis Bio has raised $70 million across 1 funding round from investors including Lilly, Atlas Venture and Medicxi. Versanis Bio operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.

  • Headquarter Oakland, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Versanis Bio, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $70 M (USD)

    in 1 rounds

  • Latest Funding Round
    $70 M (USD), Series A

    Aug 31, 2021

  • Investors
    Lilly

    & 2 more

  • Employee Count
    Employee Count
  • Acquired by
    Lilly

    (Jul 14, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Versanis Bio
Headcount
Employee Profiles 6
Board Members and Advisors 6
Employee Profiles
People
Kevin Nguyen
VP, Project Management & Operations
People
Kiran Dole
VP, Clinical Operations
People
Mark Pruzanski
Chairman & CEO
People
Ken Attie
EVP & CMO

Unlock access to complete

Board Members and Advisors
people
Michael Gladstone
Director
people
Mark Fishman
Director
people
Nick Williams
Director
people
John Maraganore
Director

Unlock access to complete

Funding Insights of Versanis Bio

Versanis Bio has successfully raised a total of $70M through 1 strategic funding round. The most recent funding activity was a Series A round of $70 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $70.0M
  • First Round

    (31 Aug 2021)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2021 Amount Series A - Versanis Bio Valuation Atlas Venture , Medicxi
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Versanis Bio

Versanis Bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Atlas Venture and Medicxi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Founded Year Domain Location
Early-stage life science focused VC firm investing in geographies such as Europe and the US
Founded Year Domain Location
Traditional pharmaceutical medicines are developed for multiple health fields.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Versanis Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Versanis Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Versanis Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Versanis Bio

Versanis Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for diabetes and obesity treatment are developed.
domain founded_year HQ Location
Vaccines for infectious diseases and solid tumors are developed.
domain founded_year HQ Location
Disease-modifying therapies for metabolic diseases are developed.
domain founded_year HQ Location
Bioinformatics platform is provided for biomarkers and drug discovery.
domain founded_year HQ Location
Endoscopic procedures for type-2 diabetes treatment are developed.
domain founded_year HQ Location
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Versanis Bio

Frequently Asked Questions about Versanis Bio

When was Versanis Bio founded?

Versanis Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Versanis Bio located?

Versanis Bio is headquartered in Oakland, United States. It is registered at Oakland, California, United States.

Who is the current CEO of Versanis Bio?

Lloyd Klickstein is the current CEO of Versanis Bio.

Is Versanis Bio a funded company?

Versanis Bio is a funded company, having raised a total of $70M across 1 funding round to date. The company's 1st funding round was a Series A of $70M, raised on Aug 31, 2021.

What does Versanis Bio do?

Versanis Bio was founded in 2020 in Oakland, United States, within the biotechnology sector. Focus is placed on developing treatments for obesity and related metabolic conditions. The primary drug candidate, bimagrumab, functions as an activin receptor type II antagonist to enhance muscle mass while decreasing fat. Operations center on advancing this therapy through clinical stages for patient applications in obesity management.

Who are the top competitors of Versanis Bio?

Versanis Bio's top competitors include Adocia, BioAge Labs and Fractyl.

Who are Versanis Bio's investors?

Versanis Bio has 3 investors. Key investors include Lilly, Atlas Venture, and Medicxi.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available